Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 2/20 | 0.37 |
| ▸ | GUSB | P08236 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | CBFB | Q13951 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835870 | 0.88 | NPY5R (0.54) | NPY5RHCRTR1HCRTR2METAP2METAP1 | |
| SCHEMBL6834554 | 0.86 | NPY5R (0.47) | NPY5R | |
| SCHEMBL6836913 | 0.84 | NPY5R (0.55) | NPY5RCTSDTGFBR1METAP1 | |
| SCHEMBL6567519 | 0.81 | NPY5R (0.49) | NPY5RPARP1PARP10HRH4 | |
| SCHEMBL6834619 | 0.79 | NPY5R (0.53) | NPY5R | |
| SCHEMBL6834518 | 0.74 | NPY5R (0.68) | NPY5RMETAP2METAP1CBFB | |
| SCHEMBL6831686 | 0.68 | KDM4E (0.48) | NPY5R | |
| SCHEMBL6831684 | 0.68 | NPY5R (0.45) | NPY5R | |
| SCHEMBL6835192 | 0.68 | NPY5R (0.50) | NPY5RPARP1PARP10 | |
| SCHEMBL6835176 | 0.67 | NPY5R (0.51) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | NPY5R 983/4885HCRTR1 800/4885HCRTR2 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.